GFAP-Driven GFP Expression in Activated Mouse Müller Glial Cells Aligning Retinal Blood Vessels Following Intravitreal Injection of AAV2/6 Vectors
Open accessThe DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Müller cell gliosis occurs in various retinal pathologies regardless of the underlying cellular defect. Because activated Müller glial cells span the entire retina and align areas of injury, they are ideal targets for therapeutic strategies, including gene therapy. METHODOLOGY/PRINCIPAL FINDINGS: We used adeno-associated viral AAV2/6 vectors to transduce mouse retinas. The transduction pattern of AAV2/6 was investigated by studying expression of the green fluorescent protein (GFP) transgene using scanning-laser ophthalmoscopy and immuno-histochemistry. AAV2/6 vectors transduced mouse Müller glial cells aligning the retinal blood vessels. However, the transduction capacity was hindered by the inner limiting membrane (ILM) and besides Müller glial cells, several other inner retinal cell types were transduced. To obtain Müller glial cell-specific transgene expression, the cytomegalovirus (CMV) promoter was replaced by the glial fibrillary acidic protein (GFAP) promoter. Specificity and activation of the GFAP promoter was tested in a mouse model for retinal gliosis. Mice deficient for Crumbs homologue 1 (CRB1) develop gliosis after light exposure. Light exposure of Crb1(-/-) retinas transduced with AAV2/6-GFAP-GFP induced GFP expression restricted to activated Müller glial cells aligning retinal blood vessels. CONCLUSIONS/SIGNIFICANCE: Our experiments indicate that AAV2 vectors carrying the GFAP promoter are a promising tool for specific expression of transgenes in activated glial cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






![Figure 7 Light-induced GFP expression in AAV2/6-GFAP-GFP transduced Crb1−/− Müller glial cells. Crb1−/− mice, three weeks of age, were intravitreally injected with AAV2/6-GFAP-GFP (8×109 genome copies; n = 3). At 21 days after injection, before light exposure, retinal degeneration and fluorescence were analyzed by SLO at 830 nm (A) and 488 nm (B), respectively. 10 weeks after transduction the mice were exposed to white light (3000 lux) for 72 hours. GFAP-driven GFP expression was detected by SLO in Crb1−/− mice (n = 7) (C). One out of seven Crb1−/− animals showed severe retinal degeneration on SLO analysis as reported before [20], [24] (D). The retinas showed extensive fluorescence in one quadrant of the retina (F). In the severely affected retina (E), most GFP and glutamine synthetase positive Müller glial cells were found at the border of the area of ONL degeneration (G and H). Slices adjacent to the one showing the overview in E were subjected to immunohistochemistry with antibodies against glutamine synthetase. G', H' and I' are the positions of the figures G, H and I taken from adjacent slices to the overview shown in E. The asterisk in (H) points at the abnormal structure of the activated Müller glial cells and glial scar formation. In the middle of the degenerative area, the ONL is completely lost (E). In this area, highly auto-fluorescent patches of cell debris, indicated by arrowheads (I), accounted for most of the fluorescent signal found on SLO. Symbols/abbreviations used in panels: Arrow; Müller glial cells, ONL; outer nuclear layer, INL; inner nuclear layer, IPL; inner plexiform layer, GCL; ganglion cell layer.](https://figures.cochat.ai/paper-figures/e684a57195bf478bb65c808206b2a6f5/gfap-driven-gfp-expression-in-activated-mouse-muller-glial-cells-aligning-figure-7.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, rAAV2.7m8 was shown to cross the inner limiting membrane in the retina, where other naturally occurring AAV serotypes, including its parental AAV2, have poor retina penetration (Aartsen et al., 2010; Dalkara et al., 2009; Dalkara et al., 2013; Giove et al., 2010; Hellstrom et al., 2009).”
From Structure comparison of the chimeric AAV2.7m8 vector with parental AAV2 (2020) · cites this paper as Aartsen et al., 2010
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Stress (GFAP promoter) or hypoxia-driven GFAP promoters (HRSE-6xHRE-GfaABC1D) have been generated that might be safer for cells that are sensitive to continuous overexpressed artificial gene vectors [96,97,99,100,102].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [99]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Enzymatic digestion (proteasome inhibitors) of the ILM or ILM/outer limiting membrane (OLM) or disruptions of the ILM/OLM by the disease can alter rAAV infection and allow rAAV infection deeper into the retina [99,294,304,305].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [99]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, under the disease condition or enzymatic digestion of the ILM, all rAAV (1, 2, 5, 8, and 9) traversed, most likely via Müller glial cells, to RPE cells through the retina [99,304,308].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [99]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Cell stress-induced expression was observed upon induction of gliosis, by light or application of ciliary neurotrophic factor (CNTF), in Crb1-deficient retina injected intravitreally with rAAV.GFAP.eGFP[99].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [99]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Self-citationMüller cells in the healthy and diseased retina
BRINGMANN, A., PANNICKE, T., GROSCHE, J., FRANCKE, M., WIEDEMANN, P., SKATCHKOV, S., OSBORNE, N., & REICHENBACH, A. (2006) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2006.05.003 · Cited by 1,711 · cited 2×
“In most, if not all, retinopathies, independent of the underlying cellular defect Müller glial cells become activated [1].”
BackgroundVascular endothelial growth factors and angiogenesis in eye disease
Witmer, A. (2003) · Progress in Retinal and Eye Research · doi:10.1016/s1350-9462(02)00043-5 · Cited by 927 · cited 1×
“However, the dedifferentiated state of activated Müller glial cells also contributes to neuronal stress due to impairment of their neurosupportive activities [4].”
BackgroundCideciyan, A. V., Aleman, T. S., Boye, S. L., Schwartz, S. B., Kaushal, S., Roman, A. J., Pang, J.-J., Sumaroka, A., Windsor, E. A. M., Wilson, J. M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807027105 · Cited by 673
Mutations in a human homologue of Drosophila crumbs cause retinitis pigmentosa (RP12)
den Hollander, A. I., ten Brink, J. B., de Kok, Y. J. M., van Soest, S., van den Born, L. I., van Driel, M. A., van de Pol, D. J. R., Payne, A. M., Bhattacharya, S. S., Kellner, U., et al. (1999) · Nature Genetics · doi:10.1038/13848 · Cited by 468 · cited 1×
“are related to LCA and severe forms of retinitis pigmentosa (RP), which are characterized by progressive retinal degeneration causing blindness at birth or early adulthood, respectively”
BackgroundControl of Müller glial cell proliferation and activation following retinal injury
Dyer, M. A., & Cepko, C. L. (2000) · Nature Neuroscience · doi:10.1038/78774 · Cited by 442 · cited 1×
“This activation is characterized by the induction of glial fibrillary acidic protein (GFAP) and the downregulation of p27 and cyclin D3 [2].”
BackgroundHarada, T., Harada, C., Kohsaka, S., Wada, E., Yoshida, K., Ohno, S., Mamada, H., Tanaka, K., Parada, L. F., & Wada, K. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-21-09228.2002 · Cited by 397
Mehalow, A. K. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg232 · Cited by 376 · cited 1×
“It has been demonstrated in CRB1-deficient (Crb1) mice that the absence of functional CRB1 leads to a loss of interaction between Müller glial cells and photoreceptor cells which causes retinal disorganization followed relatively late by retinal degeneration accompanied by Müller cell gliosis [19,20].”
BackgroundInner limiting membrane barriers to aav-mediated retinal transduction from the vitreous
Dalkara, D., Kolstad, K. D., Caporale, N., Visel, M., Klimczak, R. R., Schaffer, D. V., & Flannery, J. G. (2009) · Molecular Therapy · doi:10.1038/mt.2009.181 · Cited by 357 · cited 2×
“When injected intravitreally, the inner limiting membrane (ILM) might act as a barrier to efficient transduction of the retina [13].”
BackgroundNitric Oxide: A Review of Its Role in Retinal Function and Disease
GOLDSTEIN, I. M., OSTWALD, P., & ROTH, S. (1996) · Vision Research · doi:10.1016/0042-6989(96)00017-x · Cited by 313
Cellular remodeling in mammalian retina: Results from studies of experimental retinal detachment
Fisher, S. K., Lewis, G. P., Linberg, K. A., & Verardo, M. R. (2005) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2004.10.004 · Cited by 298 · cited 1×
“Firstly, intravitreal administration would be potentially less deleterious to an already weakened and diseased retina [32,33].”
BackgroundWahlin, K. J., Campochiaro, P. A., Zack, D. J., & Adler, R. (2000) · PubMed · Cited by 256
van de Pavert, S. A., Kantardzhieva, A., Malysheva, A., Meuleman, J., Versteeg, I., Levelt, C., Klooster, J., Geiger, S., Seeliger, M. W., Rashbass, P., et al. (2004) · Journal of Cell Science · doi:10.1242/jcs.01301 · Cited by 250
Self-citationKlimczak, R. R., Koerber, J. T., Dalkara, D., Flannery, J. G., & Schaffer, D. V. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007467 · Cited by 210 · cited 2×
“throughout the retina, not limited to Müller cells aligning the major blood vessels [37].”
BackgroundVision 1 Year after Gene Therapy for Leber's Congenital Amaurosis
Cideciyan, A. V., Hauswirth, W. W., Aleman, T. S., Kaushal, S., Schwartz, S. B., Boye, S. L., Windsor, E. A. M., Conlon, T. J., Sumaroka, A., Roman, A. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0903652 · Cited by 199
Klein, R. L., Dayton, R. D., Tatom, J. B., Henderson, K. M., & Henning, P. P. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300331 · Cited by 196 · cited 1×
“. Moreover, the viral titer and the promoter used to drive the transgene have great influence on the level and pattern of expression”
BackgroundCRB1 mutation spectrum in inherited retinal dystrophies
den Hollander, A. I., Davis, J., van der Velde-Visser, S. D., Zonneveld, M. N., Pierrottet, C. O., Koenekoop, R. K., Kellner, U., van den Born, L. I., Heckenlively, J. R., Hoyng, C. B., et al. (2004) · Human Mutation · doi:10.1002/humu.20093 · Cited by 188 · cited 1×
“In humans, mutations in CRB1 are related to LCA and severe forms of retinitis pigmentosa (RP), which are characterized by progressive retinal degeneration causing blindness at birth or early adulthood, respectively [21,22].”
BackgroundMolecular evolution of adeno-associated virus for enhanced glial gene delivery
Koerber, J. T., Klimczak, R., Jang, J.-H., Dalkara, D., Flannery, J. G., & Schaffer, D. V. (2009) · Molecular Therapy · doi:10.1038/mt.2009.184 · Cited by 181 · cited 1×
“Briefly, plasmids containing the transgene flanked by the ITRs were cotransfected with the AAV2/6 helper plasmid pDP6 (Plasmid Factory, Bielefeld, Germany) into HEK293T cells to generate cross-packaged AAV2/6 viral vectors [12,36].”
MethodHermens, W. T. J. M. C., Brake, O. T., Dijkhuizen, P. A., Sonnemans, M. A. F., Grimm, D., Kleinschmidt, J. A., & Verhaagen, J. (1999) · Human Gene Therapy · doi:10.1089/10430349950017563 · Cited by 180 · cited 1×
“AAV stocks were generated and purified as described previously [41].”
MethodSelf-citationIn vivo confocal imaging of the retina in animal models using scanning laser ophthalmoscopy
Seeliger, M. W., Beck, S. C., Pereyra-Muñoz, N., Dangel, S., Tsai, J.-Y., Luhmann, U. F. O., van de Pavert, S. A., Wijnholds, J., Samardzija, M., Wenzel, A., et al. (2005) · Vision Research · doi:10.1016/j.visres.2005.08.014 · Cited by 171 · cited 1×
“SLO was performed with the Heidelberg Retina Angiograph 2 (HRA 2; Heidelberg Engineering, Heidelberg, Germany) as described previously [43].”
MethodSelf-citationGene therapy progress and prospects: the eye
Bainbridge, J. W., Tan, M. H., & Ali, R. R. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302812 · Cited by 162 · cited 1×
“Because of their crucial role in retinal disease, Müller glial cells are important targets for gene therapy [5].”
BackgroundSelf-citationDifferential expression of GFAP in early v late AMD: a quantitative analysis
Wu, K. H. C. (2003) · British Journal of Ophthalmology · doi:10.1136/bjo.87.9.1159 · Cited by 157 · cited 2×
“GFAP is not only upregulated, but also actively involved in the morphological changes of Müller glial cells that follow experimental retinal detachment [33] and age-related macular degeneration (AMD) [38].”
BackgroundHellström, M., Ruitenberg, M. J., Pollett, M. A., Ehlert, E. M. E., Twisk, J., Verhaagen, J., & Harvey, A. R. (2009) · Gene Therapy · doi:10.1038/gt.2008.178 · Cited by 142 · cited 3×
“Briefly, plasmids containing the transgene flanked by the ITRs were cotransfected with the AAV2/6 helper plasmid pDP6 (Plasmid Factory, Bielefeld, Germany) into HEK293T cells to generate cross-packaged AAV2/6 viral vectors [12,36].”
BackgroundMethodSelf-citationAAV-mediated gene therapy for retinal disorders: from mouse to man
Buch, P. K., Bainbridge, J. W., & Ali, R. R. (2008) · Gene Therapy · doi:10.1038/gt.2008.66 · Cited by 134 · cited 1×
“Of the viral vectors that have been tested in retinal gene transfer, those derived from the adeno-associated virus (AAV) are regarded as most promising [6].”
BackgroundSelf-citationTowards understanding CRUMBS function in retinal dystrophies
Richard, M., Roepman, R., Aartsen, W. M., van Rossum, A. G. S. H., den Hollander, A. I., Knust, E., Wijnholds, J., & Cremers, F. P. M. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl195 · Cited by 131 · cited 3×
“CRB1 encodes a transmembrane protein that is localized in Müller glial cells [17] at the subapical region (SAR) just above the adherens junctions (AJs) that form the outer limiting membrane (OLM).”
BackgroundInfluentialSelf-citationAbnormal Reactivity of Müller Cells after Retinal Detachment in Mice Deficient in GFAP and Vimentin
Verardo, M. R., Lewis, G. P., Takeda, M., Linberg, K. A., Byun, J., Luna, G., Wilhelmsson, U., Pekny, M., Chen, D.-F., & Fisher, S. K. (2008) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.07-1474 · Cited by 126 · cited 2×
“detachment [33] and age-related macular degeneration (AMD) [38].”
BackgroundHarvey, A. R., Kamphuis, W., Eggers, R., Symons, N. A., Blits, B., Niclou, S., Boer, G. J., & Verhaagen, J. (2002) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.2002.1168 · Cited by 114 · cited 1×
“For example, more ganglion cells were transduced by AAV2/2 when delivered to the adult rat retina compared with delivery at P0 [14].”
Self-citationMacular holes: vitreoretinal relationships and surgical approaches
Bainbridge, J. W., Herbert, E. N., & Gregor, Z. J. (2008) · Eye · doi:10.1038/eye.2008.23 · Cited by 105 · cited 1×
“While collagenase treatment is not applicable to patients, ILM peeling or lifting is [34] and might be used as a way to administer AAV2/6 to the human retina in order to transduce human Müller glial cells.”
Backgroundvan Rossum, A. G. S. H., Aartsen, W. M., Meuleman, J., Klooster, J., Malysheva, A., Versteeg, I., Arsanto, J.-P., Le Bivic, A., & Wijnholds, J. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl194 · Cited by 104
Self-citationvan de Pavert, S. A., Meuleman, J., Malysheva, A., Aartsen, W. M., Versteeg, I., Tonagel, F., Kamphuis, W., McCabe, C. J., Seeliger, M. W., & Wijnholds, J. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3496-06.2007 · Cited by 77
Self-citationCrb1 is a determinant of retinal apical Müller glia cell features
van de Pavert, S. A., Sanz, A. S., Aartsen, W. M., Vos, R. M., Versteeg, I., Beck, S. C., Klooster, J., Seeliger, M. W., & Wijnholds, J. (2007) · Glia · doi:10.1002/glia.20561 · Cited by 75
Self-citationBlits, B., Derks, S., Twisk, J., Ehlert, E., Prins, J., & Verhaagen, J. (2009) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2009.10.009 · Cited by 72 · cited 1×
“After DNAse treatment, the crude lysate was loaded onto an iodixanol density gradient (Sigma, St Louis, Mo, USA) and centrifuged for 70 min in a Beckman XL-100K ultracentrifuge at 69000 rpm at 16uC [42].”
MethodSelf-citationGreenberg, K. P., Geller, S. F., Schaffer, D. V., & Flannery, J. G. (2007) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.05-1570 · Cited by 68 · cited 1×
“rat retina, when delivered subretinally by lenti-viral vectors [40].”
GFAP Promoter Drives Müller Cell–Specific Expression in Transgenic Mice
Kuzmanovic, M., Dudley, V. J., & Sarthy, V. P. (2003) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.02-1265 · Cited by 62 · cited 4×
“Previously, in transgenic mice, it has been shown that the GFAP promoter can drive green fluorescent protein (GFP) expression specifically in Müller glial cells and that this expression is induced once the cells are activated [16].”
BackgroundInfluentialRegulation of Eye Size by the Retinal Basement Membrane and Vitreous Body
Halfter, W. M., Winzen, U., Bishop, P. N., & Eller, A. W. (2006) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.05-1480 · Cited by 61 · cited 2×
“To overcome this barrier, AAV2/6-CMV-GFP was intravitreally administrated after disruption of the ILM by collagenase VII treatment [27].”
MethodMpp4 recruits Psd95 and Veli3 towards the photoreceptor synapse
Aartsen, W. M., Kantardzhieva, A., Klooster, J., van Rossum, A. G. S. H., van de Pavert, S. A., Versteeg, I., Cardozo, B. N., Tonagel, F., Beck, S. C., Tanimoto, N., et al. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl047 · Cited by 52 · cited 1×
“Sections used for immunohistochemical analysis [44] were rehydrated in PBS and blocked for 1 h in 10% normal goat serum (Jackson ImmunoResearch, Suffolk, UK), 0.”
MethodSelf-citationWang, Y., Smith, S. B., Ogilvie, J. M., McCool, D. J., & Sarthy, V. (2002) · Current Eye Research · doi:10.1076/ceyr.24.4.305.8408 · Cited by 50 · cited 2×
“activation [28] as was confirmed by the absence of fluorescent signal at 21 days after injection of AAV2/6-GFAP-GFP.”
BackgroundAAV-mediated gene transfer for retinal diseases
Allocca, M., Tessitore, A., Cotugno, G., & Auricchio, A. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.12.1279 · Cited by 44 · cited 3×
“The efficacy and safety of AAV vectors has recently been demonstrated in Leber’s congenital amaurosis (LCA) patients with RPE65 mutations [8–11].”
InfluentialTransplantation prospects for the inner retina
Johnson, T. V., Bull, N. D., & Martin, K. R. G. (2008) · Eye · doi:10.1038/eye.2008.376 · Cited by 37 · cited 2×
“The ILM is thinner at the site of the major retinal blood vessels [25] and is known to be a major obstacle to cell migration after stem cell transplantation from the vitreal side of the retina [26].”
BackgroundNeurotrophic Rescue of Photoreceptors
Zack, D. J. (2000) · Neuron · doi:10.1016/s0896-6273(00)81160-5 · Cited by 36
Luna, G., Kjellström, S., Verardo, M. R., Lewis, G. P., Byun, J., Sieving, P. A., & Fisher, S. K. (2009) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.08-2910 · Cited by 14 · cited 1×
“. Even retinal detachment caused by a subretinal injection gave rise to activation of Muller glial cells as reflected by detectable GFAP expression levels at 28 days after injecting a balanced salt solution”
BackgroundHata, Y., Enaida, H., Sassa, Y., Ueno, A., Miura, M., Hisatomi, T., Goto, Y., & Ishibashi, T. (2006) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-006-0499-8 · Cited by 11 · cited 1×
“Hata et al [35] demonstrated that the intravitreal route and the subretinal route are not harmful to the function and appearance of the retina.”
Background
Research works printed but not linked: 1
- Yanoff M Fine BS Gass JD 1996 Ocular Pathology. Mosby CV
Cited by
Pharmaceutical development of AAV-based gene therapy products for the eye
Rodrigues, G. A., Shalaev, E., Karami, T. K., Cunningham, J., Slater, N. K. H., & Rivers, H. M. (2019) · Pharmaceutical Research · doi:10.1007/s11095-018-2554-7 · Cited by 213
Novel adeno-associated viral vectors for retinal gene therapy.
Vandenberghe, L. H., & Auricchio, A. (2012) · Gene Therapy · doi:10.1038/gt.2011.151 · Cited by 131
Quinn, P. M., Buck, T. M., Mulder, A. A., Ohonin, C., Alves, C. H., Vos, R. M., Bialecka, M., van Herwaarden, T., van Dijk, E. H. C., Talib, M., et al. (2019) · Stem Cell Reports · doi:10.1016/j.stemcr.2019.03.002 · Cited by 97
“On subretinal application, AAV9 and the AAV6 variant serotype ShH10Y445F are able to efficiently infect mouse photoreceptors, MGCs, and retinal pigment epithelium, whereas AAV5 does not efficiently infect and express in mouse MGCs (Aartsen et al., 2010; Pellissier et al., 2014a).”
BackgroundSelf-citationPeynshaert, K., Devoldere, J., Minnaert, A.-K., De Smedt, S. C., & Remaut, K. (2019) · Current Eye Research · doi:10.1080/02713683.2019.1565890 · Cited by 92
Buck, T., & Wijnholds, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124197 · Cited by 92
“CHX10 164 Retinal progenitor cells [98] GFAP 2600 Müller glial cells, [99,100] GFAP 2200 Müller glial cells (Novartis) [101] GfaABC1D 686 Müller glial cells [96,97]”
BackgroundSelf-citation
Metadata
- Authors
- Aartsen, W. M., van Cleef, K. W. R., Pellissier, L. P., Hoek, R. M., Vos, R. M., Blits, B., Ehlert, E. M. E., Balaggan, K. S., Ali, R. R., Verhaagen, J., & Wijnholds, J.
- Affiliations
- Netherlands Institute for Neuroscience (NL)
- University College London (GB)
- Corresponding author
- Wijnholds, Jan
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-08-24
- Volume
- 5
- Issue
- 8
- Pages
- e12387
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC2927518
- OpenAlex
- W2013679212
- Cited by
- 41
- References
- 44
- Citations by year
- 2025: 2 · 2024: 2 · 2023: 2 · 2022: 5 · 2021: 2 · 2020: 2 · 2019: 6 · 2018: 2 · 2017: 3 · 2016: 2 · 2015: 3 · 2014: 2 · 2013: 3 · 2012: 2
- FWCI
- 1.04
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- KNAW Research Portal (The Royal Netherlands Academy of Arts and Sciences) (publishedVersion)
- HAL (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UCL Discovery (University College London) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Funders
- European Commission (200234)
- ZonMw (43200004)
- Algemene Nederlandse Vereniging ter voorkoming van Blindheid
- Landelijke Stichting voor Blinden en Slechtzienden
- Stichting Blindenhulp
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- Müller cells, glial fibrillary acidic protein promoter, adeno-associated virus gene therapy, retinal gliosis, CRB1, light-induced retinal damage, internal limiting membrane, GFP expression
- MeSH terms
- Adenoviridae, Animals, Genetic Vectors, Glial Fibrillary Acidic Protein, Humans, Injections, Neuroglia, Promoter Regions, Genetic, Retinal Vessels, Transduction, Genetic, Gene Expression, Transgenes, Green Fluorescent Proteins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.